Specialty
Aesthetics Cataract & Refractive Dermatology General Ophthalmology Glaucoma Interventional Radiology Neurology Optometry Retina Women's Health View All Courses
Course Type
Supplement Multimedia Webinar In-Person Multi-Part Collection
Search
Log In

DME in 2016: A Review of Treatment Guidelines and the Role of Early Appropriate Therapy

By: Charles C. Wykoff, MD, PhD, moderator; Caroline R. Baumal, MD; David Eichenbaum, MD; Chirag P. Shah, MD, MPH

This course has expired. You can still review the content but course credit is no longer available.

Supplement Credits: 1

This continuing medical education (CME) activity captures content from roundtable discussion held in June 2016.
This certified CME activity is designed for retina specialists and general ophthalmologists involved in the management of patients with retinal disease.

Expiration Date: Saturday, September 30, 2017
Release Date: September 2016

Learning Objectives

Upon completion of this activity, the participant should be able to:

  • Assess the most recent monotherapy and combination therapy clinical study evidence using available anti-VEGF therapies for common retinal diseases, including DME
  • Discuss the ocular and systemic effects of anti-VEGF therapies and how to educate patients on appropriate expectations
  • Develop plans to initiate treatment for conditions, such as DME, using anti-VEGF agents, as well as better understand when to change therapeutic strategies

Accreditation and Designation Statement

ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education LLC, Retina Today and New Retina MD.

CREDIT DESIGNATION STATEMENT

Evolve Medical Education LLC designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty and Disclosures

Charles C. Wykoff, MD, PhD, moderator
Retina Consultants of Houston, Blanton Eye Institute
Houston, Texas

Caroline R. Baumal, MD
New England Eye Center
Boston, Massachusetts

David Eichenbaum, MD
Retina Vitreous Associates of Florida
Tampa, Florida

Chirag P. Shah, MD, MPH
Ophthalmic Consultants of Boston
Boston, Massachusetts

It is the policy of Evolve Medical Education LLC that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve Medical

Education LLC has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Charles C. Wykoff, MD, PhD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Alcon; Alimera Sciences; Allergan; Bayer Pharmaceuticals; Clearside Biomedical; DORC International; Genentech; ONL Therapeutics; Regeneron Pharmaceuticals; and ThromboGenics NV. Grant/Research Support: Acucela; Alcon; Allegro Ophthalmics LLC; Allergan; Ampio Pharmaceuticals; Apellis Pharmaceuticals; Clearside Biomedical; Genentech; Iconic Therapeutics; Ophthotech Corporation; pSivida Corp.; Regeneron Pharmaceuticals; Roche Pharma; Santen Pharmaceutical Co., Ltd.; ThromboGenics NV; and XOMA Ltd.

Caroline R. Baumal, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Advisory Board/Speaker’s Bureau: Allergan; and Genentech.

David Eichenbaum, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Alcon; Alimera Sciences; Allergan; Genentech; Ophthotech Corporation; and Regeneron Pharmaceuticals. Grant/Research Support: Alcon; Alimera Sciences; Allergan; Genentech; Ophthotech Corporation; and River Vision. Stock/Shareholder: Hemera Biosciences; and US Retina.

Chirag P. Shah, MD, MPH, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Grant/Research Support: Genentech; and Regeneron Pharmaceuticals.

Cheryl Cavanaugh, MS, director of operations, Evolve Medical Education LLC; Emily Feinman, administrator, New Retina MD and Retina Today; Michelle Dalton, writer; and Melanie Lawler, PhD, reviewer, have no financial relationships with commercial interests.

Disclaimer

OFF-LABEL STATEMENT

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve Medical Education LLC, New Retina MD, Retina Today, or Regeneron Pharmaceuticals.

DME in 2016: A Review of Treatment Guidelines and the Role of Early Appropriate Therapy

Charles C. Wykoff, MD, PhD, moderator; Caroline R. Baumal, MD; David Eichenbaum, MD; Chirag P. Shah, MD, MPH

BackNext